Decades of market consolidation in the U.S. have resulted in problems like the one millions of American families are now facing. Four companies — Abbott, Perrigo, Nestle and Mead Johnson — control 90% of the U.S. supply of formula.
President Biden invoked emergency powers under the Defense Production Act to try and boost production of baby formula, while ordering the use of government planes for imports to alleviate shortages.
Hospitals around the U.S. are postponing CT scans and rationing care while waiting on shipments of medical dye made in a Shanghai plant that just restarted production amid the city’s lockdown.
Abbott Laboratories reached a pact with U.S. authorities that would allow it to begin making baby formula again at a troubled plant in Michigan, a move that could help ease a supply shortfall that has rattled many parents.
The official line coming out of Covid-hit Shanghai is that business is returning to usual despite the ongoing lockdown, yet hundreds of manufacturers in the city aren’t operating at anywhere near to full capacity, if they’re up and running again at all.
At a time when companies will do just about anything to recruit and retain workers, fertility benefits have gone from novelty to a must-have for many companies.
The latest supply-chain news, analysis, trends and tools for executives in the pharmaceutical and biotech industries. Learn how pharmaceutical and biotech companies and their suppliers around the world are managing the flow of products across all channels of the enterprise. Experts sound off on forecasting and demand planning, supply-chain visibility, logistics outsourcing, inventory optimization, transportation management, warehouse management, supply-chain security, corporate social responsibility and more.
Subscribe to our Daily Newsletter!
Timely, incisive articles delivered directly to your inbox.